Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease: A Randomized Clinical Trial

神经调节 医学 经颅直流电刺激 脑深部刺激 痴呆 随机对照试验 临床试验 交叉研究 物理疗法 疾病 内科学 刺激 安慰剂 病理 帕金森病 替代医学
作者
Eva Matt,Michael Mitterwallner,Sonja Radjenovic,Daria Grigoryeva,Alexandra Weber,Elisabeth Stögmann,Alina Domitner,Anna Zettl,Sarah Osou,Roland Beisteiner
出处
期刊:JAMA network open [American Medical Association]
卷期号:8 (2): e2459170-e2459170 被引量:50
标识
DOI:10.1001/jamanetworkopen.2024.59170
摘要

Importance: Given the increasing prevalence of dementia and the limited treatment options available, ultrasound neuromodulation could serve as a novel add-on therapy to standard treatments for Alzheimer disease (AD). As ultrasound neuromodulation is still in its early stages, further research is essential to fully explore its potential in treating brain disorders. Objective: To evaluate clinical and functional imaging effects of transcranial pulse stimulation (TPS) in patients with AD. Design, Setting, and Participants: A randomized, double-blind, sham-controlled, crossover clinical trial was conducted at the Medical University of Vienna between January 1, 2017, and July 27, 2022. Sixty patients with clinically diagnosed AD receiving state-of-the-art treatment were randomly allocated to treatment sequence groups verum-sham (first cycle verum, second cycle sham, n = 30) and sham-verum (n = 30). Data analysis was performed from July 28, 2022, to September 5, 2024. Intervention: Each participant received 6 verum and 6 sham TPS sessions (6000 pulses, 0.20 mJ/mm2, 5 Hz) to frontoparietal brain areas. Main Outcomes and Measures: Neuropsychological tests, including the primary outcome Consortium to Establish a Registry for Alzheimer's Disease (CERAD) corrected total score (CTS), were performed at baseline and 1 week, 1 month, and 3 months following the stimulations in each cycle. Primary and secondary outcomes, including functional magnetic resonance imaging and Beck Depression Inventory-II, were analyzed by intention-to-treat analysis and, for sensitivity, by per protocol analysis. Results: For the intention-to-treat analysis, 60 patients between ages 51 and 82 years (mean [SD], 70.65 [8.16] years; 30 females; 30 males) were included. The CERAD CTS increased by a mean (SD) of 2.22 (6.87) points in the verum condition from 70.93 (14.27) points at baseline to 73.15 (14.90) 3 months after stimulation, while the mean (SD) score in the sham condition increased by 1.00 (6.82) point vs baseline from 71.68 (13.62] at baseline to 72.68 (14.48) 3 months after stimulation. Primary data analysis of the condition × session interaction was not significant (P = .68; partial η2 [ηp2] = 0.01), but its interaction with age was P = .003; ηp2 = 0.08, followed by post hoc analyses of age subsamples. Although several patients older than 70 years benefited from verum TPS, only the younger subgroup (≤70 years) showed significantly higher CTS increases for verum in all poststimulation sessions (condition × session: P = .005; ηp2 = 0.16). At 3 months after stimulation, for example, a mean (SD) 3.91 (7.86)-point increase was found for verum TPS in the younger patients, but a mean (SD) CTS decrease of 1.83 (5.80) was observed for sham. Memory-associated brain activation was significantly higher after verum TPS in the precuneus, visual, and frontal areas, while resting state functional connectivity was significantly upregulated in the dorsal attention network. In the per protocol sample, a significant reduction of the Beck Depression Inventory-II scores 3 months following verum TPS was found (verum baseline: 7.27 [5.87]; verum 3 months after stimulation: 5.27 [5.27]; sham baseline: 6.70 [5.65]; sham 3 months after stimulation: 6.22 [4.40]; P = .008; ηp2 = 0.23). During both verum and sham conditions, the most common observed adverse symptom was depression; no major neuropathologic change was detected in the patients by detailed neuroradiologic assessments. Conclusions and Relevance: In this randomized clinical trial of TPS in patients with AD, a 2-week verum treatment improved cognitive scores in the younger subgroup, ameliorated depressive symptoms, and induced upregulation of functional brain activation and connectivity. These findings suggest TPS may be a safe and promising add-on therapy for patients with AD receiving state-of-the-art treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT03770182.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
111发布了新的文献求助10
1秒前
2秒前
pluto的应助被科研通管家采纳,获得10
2秒前
赘婿的应助被科研通管家采纳,获得10
2秒前
DW的应助被科研通管家采纳,获得10
2秒前
科研路顺遂完成签到,获得积分10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
秋风的应助被科研通管家采纳,获得10
3秒前
完美世界的应助被科研通管家采纳,获得10
3秒前
所所的应助被科研通管家采纳,获得10
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
没可就和的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
香蕉觅云的应助被科研通管家采纳,获得30
3秒前
3秒前
pluto的应助被科研通管家采纳,获得10
4秒前
6666的应助被科研通管家采纳,获得10
4秒前
4秒前
JamesPei的应助被归璨采纳,获得10
4秒前
852的应助被科研通管家采纳,获得10
4秒前
wanci的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
科目三的应助被七七采纳,获得10
6秒前
我是666完成签到,获得积分10
6秒前
6秒前
8秒前
8秒前
tt发布了新的文献求助10
9秒前
七月十八完成签到,获得积分10
9秒前
神勇的筝发布了新的文献求助10
10秒前
ldj完成签到 ,获得积分10
10秒前
Wlin发布了新的文献求助10
10秒前
何皮皮完成签到,获得积分10
10秒前
YeSun完成签到,获得积分10
11秒前
万能图书馆的应助被马小采纳,获得10
12秒前
李卓完成签到,获得积分10
12秒前
13508104971发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640